Savings are vs. buying the same number of pouches at $64.95 each, the single-pouch price from Dec 1, 2026. 30% applies only to the first 8-pouch subscription shipment ($363.72 vs. 8 × $64.95); other options save 13%–25%. Later shipments renew at the regular subscription price.
Ends Mon Nov 30, 11:59 PM ET (8:59 PM PT).
HealthspanX / Publication archive
Explore individual publications and their study records. Read the source, the findings and the limits together.
Systematic review and meta-analysis / 2024
Meta-analysis of 8 RCTs (342 adults) found no significant pooled benefit of short-term NMN for standard glucose-control or lipid-profile outcomes.
Current Diabetes Reports
Read study recordEarly human intervention / 2026
Phase 1/2 single-arm ITP study: 25 patients received 900 mg/day NMN for 2 weeks; safety was favorable and 20% met the primary platelet-response endpoint.
Nature Medicine
Read study recordHuman randomized trial / 2026
11-man crossover study: NMN dampened some inflammatory signals after BFR exercise but also delayed repair signals and abolished a mitochondrial-content increase.
Journal of the International Society of Sports Nutrition
Read study recordSecondary human analysis / 2026
Post-hoc analysis of the Yi trial linked blood NAD levels with several laboratory measures; associations are exploratory and not causal treatment effects.
GeroScience
Read study recordHuman randomized trial / 2025
COVID-19/AKI RCT: MIB-626 strongly raised NAD+ but did not significantly improve kidney, inflammation or disease-severity outcomes versus placebo.
FASEB BioAdvances
Read study recordHuman randomized trial / 2025
Four-week randomized overdose-safety trial tested 750 and 1,500 mg/day NMN in 30 healthy adults; it informs short-term tolerability, not efficacy.
Fundamental Toxicological Sciences
Read study recordSecondary human analysis / 2024
Post-hoc analysis of the 80-person Yi trial found large interindividual NAD-response variability and exploratory associations with functional outcomes.
Mechanisms of Ageing and Development
Read study recordHuman randomized trial / 2024
60-person RCT: primary stepping outcome was null; secondary 4-m walking, blood NAD+ and selected sleep measures favored 250 mg/day NMN.
GeroScience
Read study recordEarly human intervention / 2024
Open-label study in 11 men: 250 mg/day NMN for 8 weeks increased PBMC NAD+; subgroup metabolic findings were exploratory and uncontrolled.
Endocrine Journal
Read study recordEarly human intervention / 2023
Single-arm study in 11 healthy adults: 250 mg/day NMN increased plasma NMN and NAD+ and also raised postprandial insulin, with high variability.
Clinical Nutrition ESPEN
Read study recordEarly human intervention / 2023
Translational study with a small human hypertension intervention plus mechanistic models; reported BP/vascular improvements need larger independent confirmation.
Signal Transduction and Targeted Therapy
Read study recordHuman randomized trial / 2023
28-day RCT in 30 adults: MIB-626 raised NAD+ and showed exploratory cardiometabolic changes; insulin sensitivity and physical performance were null.
The Journal of Clinical Endocrinology & Metabolism
Read study recordThe Evidence Center brings study design, findings and limitations into the same view.
